Wexford Capital’s Bristol-Myers Squibb BMY Stock Holding History

Wexford Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-17,389	Closed	-$1.01M	–	231
2023 Q3	$1.01M	Hold	17,389	–	–	0.22%	73
2023 Q2	$1.11M	Hold	17,389	–	–	0.22%	70
2023 Q1	$1.21M	Buy	+17,389	New	+$1.23M	0.25%	61
2021 Q1	–	Sell	-2,361	Closed	-$146K	–	217
2020 Q4	$146K	Sell	2,361 -78,697	-97%	-$4.84M	0.02%	155
2020 Q3	$4.89M	Sell	81,058 -108,970	-57%	-$6.56M	1.31%	21
2020 Q2	$11.2M	Buy	190,028 +117,152	+161%	+$7.01M	2.81%	8
2020 Q1	$4.06M	Buy	+72,876	New	+$4.45M	1.5%	18
2019 Q1	–	Sell	-150,315	Closed	-$7.81M	–	95
2018 Q4	$7.81M	Buy	+150,315	New	+$8.08M	0.67%	23

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Wexford Capital's BMY Position: Q4 2023 in Review

Wexford Capital sold out of Bristol-Myers Squibb (BMY) in Q4 2023, closing a stake of 17,389 shares — an estimated $1.01M sold.

Wexford Capital first reported a position in BMY in Q4 2018 and held it in 8 quarters. The position peaked at $11.2M in Q2 2020. 2,363 funds tracked by Wall St. Rank hold BMY as of Q4 2023.

Wexford Capital reported no remaining Bristol-Myers Squibb position as of Q4 2023 after selling out during the quarter.
Wexford Capital sold 17,389 Bristol-Myers Squibb shares in Q4 2023, an estimated $1.01M.
Wexford Capital first reported a position in Bristol-Myers Squibb in Q4 2018 and held it in 8 quarters.
Wexford Capital's Bristol-Myers Squibb position peaked at $11.2M in Q2 2020.
2,363 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2023.

Based on Wexford Capital's 13F filing for Q4 2023, filed 15 Feb 2024.